Atomwise

Atomwise is an artificial intelligence (AI)-driven drug discovery company that uses machine learning to discover and develop new small molecule medicines. The company's AI engine combines the power of convolutional neural networks with massive chemical libraries to identify new drug candidates. Atomwise has a wholly owned pipeline of drug discovery programs and also partners with other pharmaceutical companies to co-develop drugs. The company's investors include prominent venture capital firms and pharmaceutical companies.

Atomwise is an AI-powered drug discovery company that uses machine learning to identify new small molecule medicines. The company's platform combines the power of convolutional neural networks with massive chemical libraries to discover new drug candidates. Atomwise has a portfolio of wholly owned and co-developed pipeline assets, and is backed by prominent investors.

Recursion is a techbio company that uses artificial intelligence to accelerate drug discovery. The company's platform combines hardware, software, and data to create a more efficient and effective drug discovery process. Recursion has a broad pipeline of drug candidates in development, and it has partnered with several leading pharmaceutical companies. The company is headquartered in Salt Lake City, Utah.

Insitro is a drug discovery and development company that uses machine learning and data to identify and develop new medicines. The company's platform integrates in vitro cellular data produced in its labs with human clinical data to help redefine disease. Insitro's pipeline includes wholly-owned and partnered therapeutic programs in metabolism, oncology, and neuroscience.

Genesis Therapeutics is an AI platform that leverages cutting-edge technology to revolutionize drug discovery and development processes. The platform integrates advanced algorithms and machine learning models to accelerate the identification of novel drug candidates and optimize their properties. By combining computational simulations with experimental data, Genesis Therapeutics offers a comprehensive solution to streamline the drug development pipeline and bring innovative therapies to market faster. The platform is designed to empower researchers and pharmaceutical companies with powerful tools for predicting drug-target interactions, optimizing molecular structures, and prioritizing lead compounds for further investigation.

Variational AI is a company that uses generative AI to discover novel drug-like small molecules with optimized properties for defined targets. Their platform, Enki™, is the first commercially accessible foundation model for small molecules. It is designed to make generating novel molecule structures easy, with no data required. Users simply define their target product profile (TPP) and Enki does the rest. Enki is an ensemble of generative algorithms trained on decades worth of experimental data with proven results. The company was founded in September 2019 and is based in Vancouver, BC, Canada.

VantAI is an AI application focused on generative AI-enabled drug discovery. Their mission is to unlock a new chapter in medicine by making protein interactions programmable. They have an integrated discovery platform with phase-shifting technologies designed to unlock the full potential of the proximity modulator modality. VantAI collaborates with industry leaders to build the future of therapeutic design. The company has launched Neo-1, the first AI model to rewire molecular interactions by unifying structure prediction and generation.

Valo is a company that uses AI-driven technology to transform the discovery and development of life-changing medicines. They combine machine learning, tissue biology, and patient data to create a suite of powerful capabilities that bring the future of drug discovery and development to bear. Valo's team of software engineers, data scientists, biologists, medicinal chemists, and big-picture thinkers are dedicated to advancing the combined power of technology and patient data.

BioXcel Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing transformative medicines in neuroscience and immuno-oncology utilizing artificial intelligence, or AI, techniques. The company's proprietary AI platform is used to identify, re-innovate, and develop potential new therapies. BioXcel Therapeutics has a pipeline of product candidates in various stages of development, including BXCL501 for agitation in dementia, BXCL701 for cocaine use disorder, and BXCL801 for acute suicidal ideation and behavior in patients with major depressive disorder.

The Institute for Protein Design is a research institute at the University of Washington that uses computational design to create new proteins that solve modern challenges in medicine, technology, and sustainability. The institute's research focuses on developing new protein therapeutics, vaccines, drug delivery systems, biological devices, self-assembling nanomaterials, and bioactive peptides. The institute also has a strong commitment to responsible AI development and has developed a set of principles to guide its use of AI in research.

Intelligencia AI is a leading provider of AI-powered solutions for the pharmaceutical industry. Our suite of solutions helps de-risk and enhance clinical development and decision-making. We use a combination of data, AI, and machine learning to provide insights into the probability of success for drugs across multiple therapeutic areas. Our solutions are used by many of the top global pharmaceutical companies to improve their R&D productivity and make more informed decisions.

BenevolentAI is a leader in applying advanced AI to accelerate biopharma drug discovery blending science and technology with a focus on finding solutions for complex diseases. We empower both biopharmaceutical companies and our internal scientists to harness the full potential of data and AI to accelerate the next generation of scientific advances. We have built our AI-enabled drug discovery engine to drive a revolution in drug discovery. The Benevolent Platform™ unlocks the power of a vast biomedical data landscape to provide a multidimensional representation of human biology across all diseases. We believe this approach will improve the probability of clinical success, and help us deliver life-changing treatments to patients – because it matters.

Tempus is an AI-enabled precision medicine company that brings the power of data and artificial intelligence to healthcare. With the power of AI, Tempus accelerates the discovery of novel targets, predicts the effectiveness of treatments, identifies potentially life-saving clinical trials, and diagnoses multiple diseases earlier. Tempus's innovative technology includes ONE, an AI-enabled clinical assistant; NEXT, a tool to identify and close gaps in care; LENS, a platform to find, access, and analyze multimodal real-world data; and ALGOS, algorithmic models connected to Tempus's assays to provide additional insight.

Allchemy is a resource-aware AI platform for drug discovery. It combines state-of-the-art computational synthesis with AI algorithms to predict molecular properties. Within minutes, Allchemy creates thousands of synthesizable lead candidates meeting user-defined profiles of drug-likeness, affinity towards specific proteins, toxicity, and a range of other physical-chemical measures. Allchemy encompasses the entire resource-to-drug design process and has been used in academic, corporate and classified environments worldwide to: Design synthesizable leads targeting specific proteins Evolve scaffolds similar to desired drugs Design “circular” drug syntheses from renewable materials Interface with and instruct automated synthesis platforms and optimize pilot-scale processes Operate “iterative synthesis” schemes Predict side reactions and create forensic “synthetic signatures” of hazardous/toxic molecules Design synthetic degradation and recovery cycles for various types of feedstocks and functional target molecules

Freenome is a healthcare company that uses artificial intelligence and multiomics technology to detect cancer in its earliest stages through a simple blood draw. The company's mission is to make early cancer detection more accessible and affordable, and to improve the chances of successful treatment.

JADBio is an automated machine learning (AutoML) platform designed to accelerate biomarker discovery and drug development processes. It offers a no-code solution that automates the discovery of biomarkers and interprets their role based on research needs. JADBio can parse multi-omics data, including genomics, transcriptome, metagenome, proteome, metabolome, phenotype/clinical data, and images, enabling users to efficiently discover insights for various conditions such as cancer, immune system disorders, chronic diseases, infectious diseases, and mental health. The platform is trusted by partners in precision health and medicine and is continuously evolving to disrupt drug discovery times and costs at all stages.

Atomwise is an artificial intelligence (AI)-driven drug discovery company that uses machine learning to discover and develop new small molecule medicines. The company's AI engine combines the power of convolutional neural networks with massive chemical libraries to identify new drug candidates. Atomwise has a wholly owned pipeline of drug discovery programs and also partners with other pharmaceutical companies to co-develop drugs. The company's investors include prominent venture capital firms and pharmaceutical companies.

The Institute for Protein Design is a research institute at the University of Washington that uses computational design to create new proteins that solve modern challenges in medicine, technology, and sustainability. The institute's research focuses on developing new protein therapeutics, vaccines, drug delivery systems, biological devices, self-assembling nanomaterials, and bioactive peptides. The institute also has a strong commitment to responsible AI development and has developed a set of principles to guide its use of AI in research.

Atomwise is an AI-powered drug discovery company that uses machine learning to identify new small molecule medicines. The company's platform combines the power of convolutional neural networks with massive chemical libraries to discover new drug candidates. Atomwise has a portfolio of wholly owned and co-developed pipeline assets, and is backed by prominent investors.

Tempus is an AI-enabled precision medicine company that brings the power of data and artificial intelligence to healthcare. With the power of AI, Tempus accelerates the discovery of novel targets, predicts the effectiveness of treatments, identifies potentially life-saving clinical trials, and diagnoses multiple diseases earlier. Tempus' innovative technology includes ONE, an AI-enabled clinical assistant; NEXT, which identifies and closes gaps in care; LENS, which finds, accesses, and analyzes multimodal real-world data; and ALGOS, algorithmic models connected to Tempus' assays to provide additional insight.

Kuano is an AI tool that focuses on redefining drug discovery using Quantum and AI technologies. The platform offers world-class scientific expertise in quantum physics, AI, and medicinal chemistry to revolutionize the drug design process. Kuano aims to leverage cutting-edge technologies to accelerate the discovery of new drugs and improve healthcare outcomes.

Flora Incognita is an interactive plant species identification application that combines AI-supported plant identification with citizen science. With the ability to identify over 30,000 plant species, users can save their plant observations and access extensive plant fact sheets. The app is free of charge, advertising-free, and can be used offline, making it ideal for educational purposes and nature conservation initiatives.

System Pro is a cutting-edge platform that revolutionizes the way users conduct research, particularly in the fields of health and life sciences. It offers a fast and dependable method to discover, combine, and place scientific research in context. By leveraging advanced technology, System Pro enhances the efficiency and effectiveness of research processes, empowering users to access valuable insights with ease.

Synthace is a software and expertise platform designed for Discovery Biology Teams to streamline and optimize their experiments in assay development, media optimization, and purification process development. The platform offers software solutions, training, and on-site support from specialists to help scientists conduct experiments more efficiently and effectively. By leveraging multifactorial methods and automation, Synthace aims to accelerate drug discovery processes and deliver faster, definitive results.

Valo is a company that uses AI-driven technology to transform the discovery and development of life-changing medicines. They combine machine learning, tissue biology, and patient data to create a suite of powerful capabilities that bring the future of drug discovery and development to bear. Valo's team of software engineers, data scientists, biologists, medicinal chemists, and big-picture thinkers are dedicated to advancing the combined power of technology and patient data.

Atomwise is an artificial intelligence (AI)-driven drug discovery company that uses machine learning to discover and develop new small molecule medicines. The company's AI engine combines the power of convolutional neural networks with massive chemical libraries to identify new drug candidates. Atomwise has a wholly owned pipeline of drug discovery programs and also partners with other pharmaceutical companies to co-develop drugs. The company's investors include prominent venture capital firms and pharmaceutical companies.

Deepcell is a company that develops technology for single-cell analysis. Their REM-I platform combines label-free imaging, deep learning, and gentle sorting to leverage single cell morphology as a high-dimensional quantitative readout. This allows researchers to gain insights into cells' phenotype and function to address important research questions across biology.

Recursion is a techbio company that uses artificial intelligence to accelerate drug discovery. The company's platform combines hardware, software, and data to create a more efficient and effective drug discovery process. Recursion has a broad pipeline of drug candidates in development, and it has partnered with several leading pharmaceutical companies. The company is headquartered in Salt Lake City, Utah.

The Institute for Protein Design is a research institute at the University of Washington that uses computational design to create new proteins that solve modern challenges in medicine, technology, and sustainability. The institute's research focuses on developing new protein therapeutics, vaccines, drug delivery systems, biological devices, self-assembling nanomaterials, and bioactive peptides. The institute also has a strong commitment to responsible AI development and has developed a set of principles to guide its use of AI in research.

Allchemy is a resource-aware AI platform for drug discovery. It combines state-of-the-art computational synthesis with AI algorithms to predict molecular properties. Within minutes, Allchemy creates thousands of synthesizable lead candidates meeting user-defined profiles of drug-likeness, affinity towards specific proteins, toxicity, and a range of other physical-chemical measures. Allchemy encompasses the entire resource-to-drug design process and has been used in academic, corporate and classified environments worldwide to: Design synthesizable leads targeting specific proteins Evolve scaffolds similar to desired drugs Design “circular” drug syntheses from renewable materials Interface with and instruct automated synthesis platforms and optimize pilot-scale processes Operate “iterative synthesis” schemes Predict side reactions and create forensic “synthetic signatures” of hazardous/toxic molecules Design synthetic degradation and recovery cycles for various types of feedstocks and functional target molecules

Atomwise is an AI-powered drug discovery company that uses machine learning to identify new small molecule medicines. The company's platform combines the power of convolutional neural networks with massive chemical libraries to discover new drug candidates. Atomwise has a portfolio of wholly owned and co-developed pipeline assets, and is backed by prominent investors.

Wildlife Insights is an AI application that brings cutting-edge technology to wildlife conservation. It streamlines decision-making by providing machine learning models and tools to manage, analyze, and share camera trap data. Users can easily upload, identify, analyze, and discover wildlife through the platform, enabling better decisions to help wildlife thrive globally.

BioloGPT is an AI tool designed to answer biology-related questions with insights and graphs. It provides information on various topics such as maintaining a healthy gut microbiome, foods for a healthy immune system, effects of cannabis on the brain, risks of Covid-19 vaccines, and advancements in psoriasis treatment. The tool is updated daily and cites full papers to support its answers.

Bichos ID de Fucesa is an AI tool that allows users to explore and identify insects, arachnids, and other arthropods using artificial intelligence. Users can discover the most searched bugs, explore new discoveries made by the community, and view curated organisms. The platform aims to expand knowledge about the fascinating world of arthropods through AI-powered identification.

HoloEye.AI is a transformative AI biological intelligence company that leverages cutting-edge artificial intelligence technology to revolutionize the field of biological research. The platform offers advanced AI solutions for analyzing complex biological data, enabling researchers to gain deeper insights and accelerate scientific discoveries.

CellProfiler is an AI tool designed for biologists to analyze and process images automatically. It allows users to load image-processing modules, adjust settings, measure phenotypes, export data, and classify phenotypes using machine learning. The application is user-friendly and provides a seamless experience for biologists to analyze complex or subtle phenotypes in their images.

Salt AI is a development engine tailored for life sciences organizations, aiming to accelerate advancements in the field by enabling faster adoption and utilization of AI technologies. The platform offers reliable and reproducible AI processes, optimized for speed and efficiency, and promotes transparency and collaboration within workflows. With a focus on supporting best-in-class life sciences research models, Salt AI empowers users to enhance their understanding of biological processes through flexible and performant AI solutions.

Lavo Life Sciences is an AI-accelerated crystal structure prediction application that helps in drug development by providing accurate predictions for small molecule drugs. The application utilizes AI technology to optimize solid-state formulations, reduce turnaround time, mitigate risks, and discover novel polymorphs, ultimately streamlining the pharmaceutical research and development process.

Cradle is a protein engineering platform that uses machine learning to design improved protein sequences. It allows users to import assay data, generate new sequences, test them in the lab, and import the results to improve the model. Cradle can be used to optimize multiple properties of a protein simultaneously, and it has been used by leading biotech teams to accelerate new and ongoing projects.

C&EN, a publication of the American Chemical Society, provides the latest news and insights on the chemical industry, including research, technology, business, and policy. It covers a wide range of topics, including analytical chemistry, biological chemistry, business, careers, education, energy, environment, food, materials, people, pharmaceuticals, physical chemistry, policy, research integrity, safety, and synthesis.

Chemprop is a PyTorch-based framework for training and evaluating message-passing neural networks (MPNNs) for molecular property prediction. Originally developed for research purposes, Chemprop offers a comprehensive set of tools and features for training models and analyzing molecular representations. The package underwent a recent major release (v2.0.0) with significant improvements and updates.

Rationale is a cutting-edge decision-making tool powered by advanced AI technology, including the latest GPT model and in-context learning capabilities. It leverages artificial intelligence to provide users with valuable insights and recommendations for making informed decisions across various domains.

Mnemonic AI is an advanced Customer Intelligence tool that offers AI Personas and Digital Twin of the Customer. It helps organizations improve their understanding of individuals by creating data-driven buyer personas and virtual customers. The tool analyzes OCEAN Big Five Personality Traits and Schwartz Universal Values to tailor messages and marketing strategies. Mnemonic AI automates the process of creating personas and updating customer data, providing deep insights for informed decision-making.

functime is a time-series machine learning tool designed to perform forecasting at scale. It provides functions for scoring, ranking, and plotting thousands of forecasts simultaneously. With a focus on guiding users through their first end-to-end forecasting pipeline, functime serves as an AI copilot to analyze trends, seasonality, and causal factors in forecasts. The tool offers a comprehensive API reference and documentation, making it a valuable resource for both beginners and experienced analysts.

Kolank is an AI platform offering a unified API with agent interoperability, automatic model selection, and cost optimization. It enables AI agents to communicate and collaborate efficiently, providing access to a wide range of AI models for text, image, and video processing. With features like load balancing, fallbacks, and performance metrics, Kolank simplifies AI model integration and usage, making it a comprehensive solution for various AI tasks.